ArticleFrontiers in immunology2026
A large-scale profiling study of immune-coagulation associations in rheumatoid arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically profile associations between immunological markers and coagulation parameters in patients with rheumatoid arthritis (RA), and to evaluate the reproducibility and independence of these associations from demographic and inflammatory factors. Methods: We conducted a retrospective cross-sectional analysis of 1,656 hospitalized patients with RA. Associations between immunological markers (immunoglobulin G [IgG], immunoglobulin A [IgA], immunoglobulin M [IgM], rheumatoid factor [RF], anti-citrullinated protein antibodies [ACPA], C3, and C4) and coagulation parameters (international normalized ratio [INR], prothrombin time [PT], PT activity, activated partial thromboplastin time [APTT], D-dimer, and fibrinogen) were assessed using multivariable linear regression adjusted for age, sex, erythrocyte sedimentation rate, and high-sensitivity C-reactive protein. The cohort was divided into exploratory and validation subsets based on the median admission date. Robustness was examined using reduced-variable and principal component analysis-based sensitivity models. Results: Thirteen immune-coagulation associations were reproducibly identified across exploratory and validation cohorts. IgG showed coordinated associations with multiple coagulation parameters, including positive associations with INR, PT, APTT, and D-dimer, and negative associations with PT activity and fibrinogen. RF and ACPA exhibited inverse associations with APTT and fibrinogen, while complement components C3 and C4 were positively associated with fibrinogen levels. These patterns remained stable across sensitivity analyses, supporting the reproducibility of immune-coagulation coupling at the laboratory biomarker level. Conclusion: This large-scale profiling study delineates reproducible and internally validated associations between immunological markers and coagulation parameters in RA, revealing a structured immune-coagulation landscape at the laboratory level. Rather than implying clinical outcomes, these findings provide a reference framework to contextualize immune-coagulation interactions and support hypothesis-driven longitudinal or mechanistic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.